Transplant outcome of 44 patients receiving a nonmyeloablative regimen
Patient no. . | Toxic death . | Neutrophils > 0.5 × 109/L, days . | Platelets > 20 × 109/L, days . | Acute GVHD . | Chronic GVHD . | Current status, months . | Cause of death . |
---|---|---|---|---|---|---|---|
1 | 20* | 24 | — | No | Dead | GVHD post-DLI | |
2 | 23* | 96 | — | No | Alive in CR 26+ | — | |
3 | Yes; day +153 | 23* | 24 | — | No | Dead | Methicillin-resistant Staphylococcus aureus Pneumonia |
4 | Yes; day +21 | NE* | NE | — | NE | Dead | Sepsis |
5 | 11 | 11 | Grade I skin | No | Alive in CR 22+ | ||
6 | 12 | 11 | — | No | Alive in CR 18+ | ||
7 | 11 | 11 | — | No | Alive in CR 16+ | ||
8 | Yes; day +24 | 13 | N/A | — | NE | Dead | Pneumonitis |
9 | 10 | 15 | — | No | Alive in CR 12+ | ||
10 | Yes; day +148 | 21* | 23 | — | No | Dead | Renal failure |
11 | 18* | 13 | — | No | Alive in CR 13+ | ||
12 | 15† | 13 | — | No | Dead | Disease | |
13 | 12† | 22 | Grade II GI | No | Dead | Disease | |
14 | 13† | 15 | Grade I skin | No | Alive-progressive disease 15+ | ||
15 | 12 | 13 | — | No | Alive in CR 14+ | ||
16 | 18 | 30 | — | No | Alive in CR 11+ | ||
17 | 14 | 11 | — | No | Alive-progression-free 10+ | ||
18 | 11 | 9 | — | No | Alive-progression-free 9+ | ||
19 | 11 | 10 | — | No | Alive in CR 9+ | ||
20 | 8 | 3 | — | No | Alive-progression-free 8+ | ||
21 | 16 | 18 | — | No | Alive in CR 10+ | ||
22 | 13 | 16 | Grade I skin | Skin, liver | Alive-progression-free 10+ | ||
23 | 16 | 11 | No | Alive in PR 12+ | |||
24 | 11† | 11 | Grade II skin & GI | No | Alive in CR 11+ | ||
25 | 12 | 14 | — | No | Dead | Disease | |
26 | 14 | 18 | — | No | Alive in CR 8+ | ||
27 | 15 | 12 | — | No | Alive in CR 7+ | ||
28 | 12 | 10 | — | No | Alive in PR 7+ | ||
29 | 13 | 9 | — | No | Alive in CR 6+ | ||
30 | 13 | 18 | — | No | Alive in CR 6+ | ||
31 | 10 | 9 | — | No | Alive in CR 6+ | ||
32 | 10 | 8 | — | No | Alive in PR 5+ | ||
33 | 22† | 18 | — | No | Alive in CR 8+ | ||
34 | 12 | 13 | — | No | Alive in CR 7+ | ||
35 | 13 | 24 | — | No | Alive-progressive disease 5+ | ||
36 | 12 | 12 | — | No | Alive in CR 4+ | ||
37 | 13† | 15 | — | No | Alive in CR 5+ | ||
38 | 17 | 18 | — | No | Alive-progression-free 3+ | ||
39 | 14 | 14 | — | No | Alive-progression-free 3.5+ | ||
40 | 12 | 12 | — | No | Alive-progression-free 3+ | ||
41 | 14 | 18 | — | No | Alive in CR 3+ | ||
42 | 23 | 30 | — | No | Alive in PR 3+ | ||
43 | 13 | 27 | — | No | Alive-progressive disease 3+ | ||
44 | 15 | 11 | — | No | Alive-cytogenetic CR 3+ |
Patient no. . | Toxic death . | Neutrophils > 0.5 × 109/L, days . | Platelets > 20 × 109/L, days . | Acute GVHD . | Chronic GVHD . | Current status, months . | Cause of death . |
---|---|---|---|---|---|---|---|
1 | 20* | 24 | — | No | Dead | GVHD post-DLI | |
2 | 23* | 96 | — | No | Alive in CR 26+ | — | |
3 | Yes; day +153 | 23* | 24 | — | No | Dead | Methicillin-resistant Staphylococcus aureus Pneumonia |
4 | Yes; day +21 | NE* | NE | — | NE | Dead | Sepsis |
5 | 11 | 11 | Grade I skin | No | Alive in CR 22+ | ||
6 | 12 | 11 | — | No | Alive in CR 18+ | ||
7 | 11 | 11 | — | No | Alive in CR 16+ | ||
8 | Yes; day +24 | 13 | N/A | — | NE | Dead | Pneumonitis |
9 | 10 | 15 | — | No | Alive in CR 12+ | ||
10 | Yes; day +148 | 21* | 23 | — | No | Dead | Renal failure |
11 | 18* | 13 | — | No | Alive in CR 13+ | ||
12 | 15† | 13 | — | No | Dead | Disease | |
13 | 12† | 22 | Grade II GI | No | Dead | Disease | |
14 | 13† | 15 | Grade I skin | No | Alive-progressive disease 15+ | ||
15 | 12 | 13 | — | No | Alive in CR 14+ | ||
16 | 18 | 30 | — | No | Alive in CR 11+ | ||
17 | 14 | 11 | — | No | Alive-progression-free 10+ | ||
18 | 11 | 9 | — | No | Alive-progression-free 9+ | ||
19 | 11 | 10 | — | No | Alive in CR 9+ | ||
20 | 8 | 3 | — | No | Alive-progression-free 8+ | ||
21 | 16 | 18 | — | No | Alive in CR 10+ | ||
22 | 13 | 16 | Grade I skin | Skin, liver | Alive-progression-free 10+ | ||
23 | 16 | 11 | No | Alive in PR 12+ | |||
24 | 11† | 11 | Grade II skin & GI | No | Alive in CR 11+ | ||
25 | 12 | 14 | — | No | Dead | Disease | |
26 | 14 | 18 | — | No | Alive in CR 8+ | ||
27 | 15 | 12 | — | No | Alive in CR 7+ | ||
28 | 12 | 10 | — | No | Alive in PR 7+ | ||
29 | 13 | 9 | — | No | Alive in CR 6+ | ||
30 | 13 | 18 | — | No | Alive in CR 6+ | ||
31 | 10 | 9 | — | No | Alive in CR 6+ | ||
32 | 10 | 8 | — | No | Alive in PR 5+ | ||
33 | 22† | 18 | — | No | Alive in CR 8+ | ||
34 | 12 | 13 | — | No | Alive in CR 7+ | ||
35 | 13 | 24 | — | No | Alive-progressive disease 5+ | ||
36 | 12 | 12 | — | No | Alive in CR 4+ | ||
37 | 13† | 15 | — | No | Alive in CR 5+ | ||
38 | 17 | 18 | — | No | Alive-progression-free 3+ | ||
39 | 14 | 14 | — | No | Alive-progression-free 3.5+ | ||
40 | 12 | 12 | — | No | Alive-progression-free 3+ | ||
41 | 14 | 18 | — | No | Alive in CR 3+ | ||
42 | 23 | 30 | — | No | Alive in PR 3+ | ||
43 | 13 | 27 | — | No | Alive-progressive disease 3+ | ||
44 | 15 | 11 | — | No | Alive-cytogenetic CR 3+ |